IPCA asks USFDA to clarify on Hydroxychloroquine risk
Posted by
www.biotecnika.org
Hydroxychloroquine, besides being administered as an anti-malarial
drug, is also used as a chronic therapy by patients suffering from
auto immune diseases such as RA and Lupus. In the recent months the
drug has been used in several countries including India and US in the
treatment of critically ill Covid-19 patients.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ipca-asks-usfda-to-clarify-on-hydroxychloroquine-risk/articleshow/75462945.cms
Subscribe to:
Post Comments (Atom)
Post a Comment